iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://www.ncbi.nlm.nih.gov/pubmed/35884413
Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 10;14(14):3353.
doi: 10.3390/cancers14143353.

Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population

Aleksandra Grela-Wojewoda  1 , Mirosława Püsküllüoğlu  1 , Beata Sas-Korczyńska  2 , Tomasz Zemełka  1 , Renata Pacholczak-Madej  1   3 , Wojciech M Wysocki  4   5   6 , Tomasz Wojewoda  4   5 , Agnieszka Adamczyk  7 , Joanna Lompart  1 , Michał Korman  8 , Anna Mucha-Małecka  9 , Marek Ziobro  1 , Ewa Konduracka  10
Affiliations

Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population

Aleksandra Grela-Wojewoda et al. Cancers (Basel). .

Abstract

Trastuzumab-induced cardiotoxicity (TIC) can lead to early treatment discontinuation. The aim of this study was to evaluate: N-terminal brain natriuretic peptide (NT-proBNP), creatine kinase-MB (CK-MB), myoglobin, and selected biochemical and clinical factors as predictors of TIC. One hundred and thirty patients with HER2-positive BC receiving adjuvant trastuzumab therapy (TT) were enrolled. Measurement of cardiac markers and biochemical tests as well as echocardiography were performed prior to TT initiation and every three months thereafter. Cardiotoxicity leading to treatment interruption occurred in 24 patients (18.5%). While cardiotoxicity caused early treatment discontinuation in 14 patients (10.8%), the TIC resolved in 10 (7.7%) and TT was resumed. The most common complication was a decrease in left ventricular ejection fraction of more than 10% from baseline or below 50% (7.7%). In patients with TIC, there was no increase in the levels of NT-proBNP, myoglobin, and CK-MB. BMI, hypertension, ischemic heart disease, diabetes, age, cancer stage, type of surgery, use of radiotherapy, chemotherapy, and hormone therapy were shown to not have an effect on TIC occurrence. NT-proBNP, myoglobin, and CK-MB are not predictors of TIC. There is an ongoing need to identify biomarkers for TIC.

Keywords: HER-2 positive breast cancer; cardiac markers; cardio-oncology; cardiotoxicity; trastuzumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study design schedule of performed measurements.
Figure 2
Figure 2
Changes during therapy in levels of LVEF in patients with or without radiotherapy (A) and in patients with different occurrence of valvular insufficiency of any grade (B); in levels of NT-proBNP in patients stratified according to treatment (C) or changes in LVEF (D); in levels of myoglobin in patients with or without coexisting ischemic heart disease (E) and in patients stratified according to LVEF changes (F). * Valvular insufficiency of any grade. Abbreviations: ATC, doxorubicin (anthracycline); DC, docetaxel; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal brain natriuretic peptide; RT, radiotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shin H.R. Global Activity of Cancer Registries and Cancer Control and Cancer Incidence Statistics in Korea. J. Prev. Med. Public Health. 2008;41:84–91. doi: 10.3961/jpmph.2008.41.2.84. - DOI - PubMed
    1. Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M., Znaor A., Bray F. Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods. Int. J. Cancer. 2019;144:1941–1953. doi: 10.1002/ijc.31937. - DOI - PubMed
    1. Loibl S., Poortmans P., Morrow M., Denkert C., Curigliano G. Breast Cancer. Lancet. 2021;397:1750–1769. doi: 10.1016/S0140-6736(20)32381-3. - DOI - PubMed
    1. Zhu H., Doğan B.E. American Joint Committee on Cancer’s Staging System for Breast Cancer, Eighth Edition: Summary for Clinicians. Eur. J. Breast Health. 2021;17:234–238. doi: 10.4274/ejbh.galenos.2021.2021-4-3. - DOI - PMC - PubMed
    1. Mohanty S.S., Sahoo C.R., Padhy R.N. Role of Hormone Receptors and HER2 as Prospective Molecular Markers for Breast Cancer: An Update. Genes Dis. 2021;9:648–658. doi: 10.1016/j.gendis.2020.12.005. - DOI - PMC - PubMed